{"entity":{"id":"alexander-perl","kind":"person","name":"Alexander E. Perl","aka":[],"tldr":"Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML.","summary":"Alexander Perl was principal investigator of ADMIRAL, which showed the FLT3 inhibitor gilteritinib doubles survival versus salvage chemotherapy in relapsed or refractory FLT3-mutant AML, the first randomised trial to establish single-agent targeted therapy in the disease. He led the earlier phase 1/2 gilteritinib study and studies of resistance to FLT3 inhibition. He leads AML clinical research at Penn.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Perl%20AE%5BAuthor%5D%20gilteritinib"}],"tags":["aml","flt3","targeted-therapy"],"related":[],"cancers":["aml"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["flt3"],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":["admiral"],"people":[],"bottlenecks":[],"keyPapers":["paper-admiral-gilteritinib-flt3-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Abramson Cancer Center, University of Pennsylvania","institutionId":"penn-abramson","specialisms":["Acute myeloid leukaemia","FLT3 inhibitors","Relapsed AML","Resistance mechanisms"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Perl%20AE%5BAuthor%5D%20gilteritinib"}],"papers":[{"title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML (ADMIRAL)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1902688"},{"title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30416-3"}]},"route":"/people/alexander-perl/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"}],"trial":[{"id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/"}],"paper":[{"id":"paper-admiral-gilteritinib-flt3-nejm-2019","kind":"paper","name":"ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia","route":"/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/"}]}}